Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

Jiao Yang, Bing Zhao, Xiaoling Ling, Donghui Li, Jiuda Zhao, Yonggang Lv, Guangxi Wang, Xinlan Liu, Nanlin Li, Jin Yang

Open source

DOI
10.1186/s12885-023-10568-0
Published
2023-01-30
Container
BMC Cancer
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12885-023-10568-0,
  title = {Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China},
  author = {Jiao Yang and Bing Zhao and Xiaoling Ling and Donghui Li and Jiuda Zhao and Yonggang Lv and Guangxi Wang and Xinlan Liu and Nanlin Li and Jin Yang},
  year = {2023},
  journal = {BMC Cancer},
  doi = {10.1186/s12885-023-10568-0},
  url = {https://doi.org/10.1186/s12885-023-10568-0}
}

RIS

TY  - JOUR
TI  - Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
AU  - Jiao Yang
AU  - Bing Zhao
AU  - Xiaoling Ling
AU  - Donghui Li
AU  - Jiuda Zhao
AU  - Yonggang Lv
AU  - Guangxi Wang
AU  - Xinlan Liu
AU  - Nanlin Li
AU  - Jin Yang
PY  - 2023
JO  - BMC Cancer
DO  - 10.1186/s12885-023-10568-0
UR  - https://doi.org/10.1186/s12885-023-10568-0
ER  - 

APA

Yang, J., Zhao, B., Ling, X., Li, D., Zhao, J., Lv, Y., Wang, G., Liu, X., Li, N., & Yang, J. (2023). Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China. BMC Cancer. https://doi.org/10.1186/s12885-023-10568-0

Source records